KR20210144946A - 파킨슨병의 운동동요의 빠른 경감 - Google Patents

파킨슨병의 운동동요의 빠른 경감 Download PDF

Info

Publication number
KR20210144946A
KR20210144946A KR1020217038097A KR20217038097A KR20210144946A KR 20210144946 A KR20210144946 A KR 20210144946A KR 1020217038097 A KR1020217038097 A KR 1020217038097A KR 20217038097 A KR20217038097 A KR 20217038097A KR 20210144946 A KR20210144946 A KR 20210144946A
Authority
KR
South Korea
Prior art keywords
patient
levodopa
fpd
dose
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217038097A
Other languages
English (en)
Korean (ko)
Inventor
리차드 피. 배타이키
마틴 프리드
마이클 엠. 리프
Original Assignee
키비타스 테라퓨틱스, 인코포레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 키비타스 테라퓨틱스, 인코포레이티드. filed Critical 키비타스 테라퓨틱스, 인코포레이티드.
Publication of KR20210144946A publication Critical patent/KR20210144946A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020217038097A 2014-04-21 2014-04-21 파킨슨병의 운동동요의 빠른 경감 Ceased KR20210144946A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2014/034778 WO2015163840A1 (en) 2014-04-21 2014-04-21 Rapid relief of motor fluctuations in parkinson's disease
KR1020167032453A KR20170008754A (ko) 2014-04-21 2014-04-21 파킨슨병의 운동동요의 빠른 경감

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167032453A Division KR20170008754A (ko) 2014-04-21 2014-04-21 파킨슨병의 운동동요의 빠른 경감

Publications (1)

Publication Number Publication Date
KR20210144946A true KR20210144946A (ko) 2021-11-30

Family

ID=54332876

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217038097A Ceased KR20210144946A (ko) 2014-04-21 2014-04-21 파킨슨병의 운동동요의 빠른 경감
KR1020167032453A Ceased KR20170008754A (ko) 2014-04-21 2014-04-21 파킨슨병의 운동동요의 빠른 경감

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167032453A Ceased KR20170008754A (ko) 2014-04-21 2014-04-21 파킨슨병의 운동동요의 빠른 경감

Country Status (14)

Country Link
US (2) US20170296498A1 (enExample)
EP (2) EP3134077A4 (enExample)
JP (1) JP2017513866A (enExample)
KR (2) KR20210144946A (enExample)
CN (2) CN106659685B (enExample)
AU (2) AU2014391721B2 (enExample)
BR (1) BR112016024502A8 (enExample)
CA (1) CA2946165C (enExample)
IL (2) IL309959A (enExample)
MX (1) MX2016013741A (enExample)
RU (1) RU2698330C2 (enExample)
SG (1) SG11201608608PA (enExample)
WO (1) WO2015163840A1 (enExample)
ZA (1) ZA201607833B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014074797A1 (en) 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
EP3735298A4 (en) * 2018-01-05 2021-10-06 Impel Neuropharma Inc. INTRANASAL ADMINISTRATION OF LEVODOPA POWDER BY N BY AN OLFACTORIC PRECISION DEVICE
US11517548B2 (en) 2018-07-19 2022-12-06 Impel Pharmaceuticals Inc. Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
PT1531798E (pt) 2002-03-20 2012-09-10 Civitas Therapeutics Inc Administração pulmonar de levodopa
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
WO2008156586A2 (en) 2007-06-12 2008-12-24 Alkermes, Inc. Inhalation device for powdered substances
GB2454480A (en) * 2007-11-07 2009-05-13 Vectura Group Plc Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders
US8703809B2 (en) * 2008-06-30 2014-04-22 Novartis Ag Combination products
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
TW201304822A (zh) * 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
CN104884046A (zh) * 2012-10-22 2015-09-02 丝维塔斯治疗公司 用于快速缓解帕金森病的左旋多巴制剂
US8545878B1 (en) * 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use

Also Published As

Publication number Publication date
CN106659685B (zh) 2021-02-05
BR112016024502A8 (pt) 2021-06-29
CA2946165A1 (en) 2015-10-29
AU2014391721A1 (en) 2016-11-03
IL248445A0 (en) 2016-12-29
AU2014391721B2 (en) 2020-07-16
SG11201608608PA (en) 2016-11-29
AU2020239754A1 (en) 2021-01-14
KR20170008754A (ko) 2017-01-24
RU2016144340A (ru) 2018-05-22
EP3831375A1 (en) 2021-06-09
US20230053976A1 (en) 2023-02-23
US20170296498A1 (en) 2017-10-19
IL309959A (en) 2024-03-01
CA2946165C (en) 2022-10-18
AU2020239754B2 (en) 2022-06-23
BR112016024502A2 (pt) 2017-08-15
JP2017513866A (ja) 2017-06-01
RU2698330C2 (ru) 2019-08-26
MX2016013741A (es) 2017-04-06
EP3134077A1 (en) 2017-03-01
ZA201607833B (en) 2018-08-29
CN113209055A (zh) 2021-08-06
CN106659685A (zh) 2017-05-10
EP3134077A4 (en) 2017-12-20
RU2016144340A3 (enExample) 2018-05-22
WO2015163840A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
US12458615B2 (en) Methods for providing rapid relief of motor fluctuations in a Parkinson's disease patient
US20230053976A1 (en) Rapid relief of motor fluctuations in parkinson's disease
JP2019038857A (ja) レボドパの血漿濃度の患者間のばらつきの低減
JP2019108379A (ja) パーキンソン病の運動症状変動の迅速な緩和
HK40057047A (en) Rapid relief of motor fluctuations in parkinson's disease
HK40071377A (en) Levodopa formulations for rapid relief of parkinson’s disease
CA2888979C (en) Reducing inter-patient variability of levodopa plasma concentrations
HK1212258B (en) Levodopa formulations for rapid relief of parkinson's disease

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000